Sesh Incorporated
Sesh utilizes genomic analysis to assess the suitability of immunotherapy for cancer patients, enabling oncologists to make data-driven treatment decisions. This approach addresses the challenge that only about 20% of patients currently benefit from immunotherapy due to resistance mechanisms.
- Biotechnology
- Healthcare Technology
Updated 7 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Features
- Sesh utilizes genomic analysis to assess the suitability of immunotherapy for cancer patients, enabling oncologists to make data-driven treatment decisions. This approach addresses the challenge that only about 20% of patients currently benefit from immunotherapy due to resistance mechanisms.